(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncologys (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer, Dr. Alicia Morgans from Northwestern University presented a plenary talk discussing the treatment considerations for patients who received combination therapy for metastatic castration sensitive prostate cancer (mCSPC). This followed prior presentations from Dr. Carmel Pezaro and Dr. Neal Shore regarding the role of chemotherapy and novel androgen axis inhibitors in patients with mCSPC.
Dr. Morgans began by highlighting that, as per National Comprehensive Cancer Network (NCCN) guidelines, combination therapy with androgen deprivation therapy and another agent (apalutamide, abiraterone, docetaxel, or enzalutamide) is recommended.
While there are a number of treatment options for patients with mCSPC, there is an even greater plethora of treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), with no less than seven different agents available on the basis of prior therapies received, patient characteristics, and tumor characteristics.
Clearly, prior lines of therapy (including those used in the mCSPC space) influence future treatment choices when the patient progresses to mCRPC. In the mCRPC disease space, treatment choices may be guided by the following factors, among others:
1. prior treatment received, with a preference for novel mechanisms of action2. treatment availability in practice setting/location3. presence of visceral metastasis or restriction to bone-only metastasis4. candidacy for chemotherapy, on the basis of patient comorbidity and frailty5. histologic characteristics, including the presence of small cell/neuroendocrine differentiation6. targetable genetic or genomic characteristics including actionable DNA damage repair mutations or presence of microsatellite instability high status7. availability of clinical trials
Dr. Morgans highlighted that resistance mechanisms can spread through metastasis-to-metastasis seeding and similar resistance patterns are often seen in geographic proximity suggesting an element of interclonal cooperativity. As a result, at the time of disease progression, the use of therapy with a novel treatment mechanism is necessary to counter to acquired resistance.
As a general principle, Dr. Morgans outlined that sequencing of androgen axis inhibitors (including abiraterone acetate, enzalutamide, apalutamide, and darolutamide) is generally poorly effective. To drive home this point, Dr. Morgans reviewed data from the CARD trial which randomized patients who had progression on one androgen axis targeting agent to a switch or to cabazitaxel. Only 14% of patients who switched to the other androgen axis targeting agent had a PSA response of 50% or more and median progression-free survival was only 2.7 months (95% confidence interval 2.4 to 2.8 months) in contrast to median progression-free survival of 4.4 months (95% confidence interval 3.6 to 5.4 months) among those randomized to cabazitaxel (hazard ratio 0.52, 95% confidence interval 0.40 to 0.68). Similarly, in PROfound, patients who had disease progression on a novel androgen axis inhibitor were randomized to physicians choice of therapy (often including a switch to another androgen axis inhibitor) or Olaparib. As with the CARD trial, patients randomized to a second androgen axis inhibitor had median progression-free survival of 3.55 months (hazard ratio 0.34, 95% confidence interval 0.25 to 0.47).
Apart from these randomized data, there are a number of other studies that have assessed response rates for sequencing of androgen axis targeting agents demonstrates generally short progression-free survival.
Dr. Morgans then highlighted data that may guide specific treatment considerations in particular populations. First, she reviewed data from the PROCEED observational registry of patients treated with sipuleucel-T. In a prostate-specific antigen (PSA) matched analysis, median overall survival was significantly longer for African American men (35.3 months) as compared to Caucasian men (25.8 months) (hazard ratio 0.70, 95% confidence interval 0.57 to 0.86). Further, baseline PSA at the time of initiating sipuleucel-T therapy was associated with survival patients with PSA below the median (29.5 ng/mL) had improved survival (hazard ratio 0.52, 95% confidence interval 0.37 to 0.72).
In an international early access program, observational data suggested that asymptomatic patients receiving radium-223 had significantly improved overall survival compared to those who were symptomatic at the initiation of therapy (hazard ratio 0.49, 95% confidence interval 0.33 to 0.73).
Beyond clinicodemographic factors, Dr. Morgans discussed genetic and genomically targeted approaches. She first examined data from TRITON2 in which patients with mCRPC and deleterious mutations in DNA defect repair (DDR) genes who had progressed on androgen axis targeting agents received rucaparib in a single-arm design. The vast preponderance of patients had a beneficial PSA response. Subsequently, the PROfound study reported a randomized comparison of Olaparib versus physicians choice among a similar patient population. They demonstrated significantly improved radiographic progression-free survival among those receiving olaparib (median 5.8 months) versus physicians choice of therapy (median 3.5 months; hazard ratio 0.49, 95% confidence interval 0.38 to 0.63). Great detail regarding the data for PARP inhibitors in prostate cancer is provided in a UroToday Center of Excellence article.
On the basis of these data, rucaparib has been approved for men with BRCA1/2 mutations who have progressed following androgen receptor-targeted therapy and taxane chemotherapy while olaparib has been approved for men with Homologous Recombination Repair (HRR) mutations following androgen receptor-targeted therapy, with or without prior taxane treatment.
Beyondpoly ADP ribose polymerase (PARP) inhibitors, pembrolizumab is another targeted option for men with advanced prostate cancer. In this case, patients must have microsatellite instability-high status to be eligible, as the United States Federal Drug Administration (FDA) has approved pembrolizumab in a tissue agnostic fashion for patients with microsatellite instability-high tumors. Dr. Morgans reported that approximately 2-3% of men with prostate cancer will have microsatellite instability-high tumors, and are therefore expected to have radiographic responses to pembrolizumab.
Dr. Morgans closed by highlighting the importance of shared decision making for patients with advanced prostate cancer. This is particularly important where there are so many treatment options. Patient preferences may be driven by home or work obligations, by past or vicarious experiences or fears, by insurance restrictions, and other factors.
Moving forward, Dr. Morgans highlighted the potential for theranostics, including the therapeutic role of Lutetium-177-prostate-specific membrane antigen (LuPSMA). A number of ongoing trials will assess the role of Lu-PSMA, including in a comparison against cabazitaxel in patients who have progressed following docetaxel and in comparison against best supportive or standard of care in patients who have progressed following both taxane chemotherapy and an androgen axis inhibitor.
Presented by: Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois
Written by:Christopher J.D. Wallis, Urologic Oncology Fellow, Vanderbilt University Medical Center,@WallisCJD on Twitteratthe ASCO20 Virtual Education Program, #ASCO20, August 8-10, 2020.
More here:
- IOM not webcast today. Why Not? - November 8th, 2009 [November 8th, 2009]
- National Academies skeptical at Best. - November 8th, 2009 [November 8th, 2009]
- Some Confusion Exists - November 8th, 2009 [November 8th, 2009]
- Why DTC Genomics IS Medicine. - November 8th, 2009 [November 8th, 2009]
- First Mari, Now Linda. Who's next? - November 8th, 2009 [November 8th, 2009]
- Is it true? - November 8th, 2009 [November 8th, 2009]
- Re-Reviewing the National Academies - November 8th, 2009 [November 8th, 2009]
- The problem with nonclinicians....... - November 8th, 2009 [November 8th, 2009]
- Crazy Night of Emails to Government - November 8th, 2009 [November 8th, 2009]
- Adrienne Carlson's Personalized Medicine. - November 8th, 2009 [November 8th, 2009]
- Tell Me, How do you feel now? Sherpa's RX - November 8th, 2009 [November 8th, 2009]
- This Just In. 23andMe to go to GPs. I love my readers!! - November 8th, 2009 [November 8th, 2009]
- Sorry so long away - November 8th, 2009 [November 8th, 2009]
- 2D6 Rears its ugly head..... - November 8th, 2009 [November 8th, 2009]
- Ok, Fine, Back to Plavix - November 8th, 2009 [November 8th, 2009]
- Kaiser a protoype for Collins' Aim - November 8th, 2009 [November 8th, 2009]
- A few months late to the party.... - November 8th, 2009 [November 8th, 2009]
- Stated Another Way....... - November 8th, 2009 [November 8th, 2009]
- Excuse Me? Harvard and Navigenics? WTF? - November 8th, 2009 [November 8th, 2009]
- Follow up to Yesterday's WTF? Harvard, Navi? and Pfizer??? - November 8th, 2009 [November 8th, 2009]
- Did you get your kit? Thanks Dr. Rob from MedCo - November 8th, 2009 [November 8th, 2009]
- Gluco...Wha? Parkinson's Disease and Glucocerebrosidase mutations. - November 8th, 2009 [November 8th, 2009]
- Away and now back, What did I miss???? 23andme layoffs? Selling Genomes for cheap up next! - November 8th, 2009 [November 8th, 2009]
- Change IS Needed. I agree with William, sometimes. - November 8th, 2009 [November 8th, 2009]
- Good Enough Science? Apparently so at 23andme - November 8th, 2009 [November 8th, 2009]
- Long QT Syndrome, location matters - December 13th, 2009 [December 13th, 2009]
- Congratulations Generation Health. Nice pick up! - December 13th, 2009 [December 13th, 2009]
- An argument 23andSerge can't win...23andme but not medicine - December 13th, 2009 [December 13th, 2009]
- Stop. Breathe. Repeat. An analysis of the direction of DTC Genomics Field. - December 13th, 2009 [December 13th, 2009]
- Hey DTC genomics, Stay Private, Stay Alive, Go Public and Die - December 13th, 2009 [December 13th, 2009]
- You can't have it both way. Either scared your genome is sold off or not. - December 13th, 2009 [December 13th, 2009]
- 15 Days Away Gives Time for Perspective. - December 13th, 2009 [December 13th, 2009]
- What about the SACGHS registry? Another missed opportunity? - December 13th, 2009 [December 13th, 2009]
- AJHG is in and my Favorite Muin is in it! But He Is NOT the Father! - December 13th, 2009 [December 13th, 2009]
- Navigenics for 23andMe prices? - December 18th, 2009 [December 18th, 2009]
- Lp(a) Maybe there's something there that wasn't there before? - December 24th, 2009 [December 24th, 2009]
- Another Year, Another Bankruptcy - December 31st, 2009 [December 31st, 2009]
- 5 Technologies going bye bye in this decade? - January 6th, 2010 [January 6th, 2010]
- Hackers, HITECH and HIPAA in DTC Genomics, Oh My! - January 7th, 2010 [January 7th, 2010]
- Personal Genomics Flop.....big Belly Flop! - January 8th, 2010 [January 8th, 2010]
- Gotta Love It. Even the daycare....... - January 11th, 2010 [January 11th, 2010]
- Congratulations Navigenics. You ARE a clinical lab! Uh-Oh... - January 12th, 2010 [January 12th, 2010]
- CETP, Jewish Centenarians and Alzheimers - January 14th, 2010 [January 14th, 2010]
- Enter the "Not" DTC Genomics Rep - January 17th, 2010 [January 17th, 2010]
- Why Dr. Vanier's Navigenics appointment is good for PM - January 22nd, 2010 [January 22nd, 2010]
- Holy Crap! MedCo Follows in CVS footsteps - February 3rd, 2010 [February 3rd, 2010]
- FDA, Warfarin, still not as sexy to me. - February 5th, 2010 [February 5th, 2010]
- Hype, Hype, Hype from a single study. - February 11th, 2010 [February 11th, 2010]
- I love my readers, even Renata M! - February 17th, 2010 [February 17th, 2010]
- How can insurers use DTC genomics to profile? - February 17th, 2010 [February 17th, 2010]
- 9p21.....ahem. Paynter et.al. Smackdown. Again. - February 18th, 2010 [February 18th, 2010]
- Hey! It's Pete Hulick! Are you Going to GET? - February 19th, 2010 [February 19th, 2010]
- I was wrong......AHEM - February 28th, 2010 [February 28th, 2010]
- G2C2, finally a tool for genomic education! - March 2nd, 2010 [March 2nd, 2010]
- Just 4 million? What 23andMe is worth. - March 5th, 2010 [March 5th, 2010]
- What a difference a year makes - March 9th, 2010 [March 9th, 2010]
- ........DTC Genomic Medicine? - March 12th, 2010 [March 12th, 2010]
- The FDA, 2c19 and the ACC - March 13th, 2010 [March 13th, 2010]
- The problem with Comparative Whole Genomics...... - March 13th, 2010 [March 13th, 2010]
- BRCA testing by 23andME is the same as Myriad Genetics. - March 15th, 2010 [March 15th, 2010]
- The Argument Against DTC Genomics Marketing and such - March 16th, 2010 [March 16th, 2010]
- A moment of Clarity. Some DTCG is not bad. - March 18th, 2010 [March 18th, 2010]
- SNPs for breast cancer risk? It Depends. - March 18th, 2010 [March 18th, 2010]
- How can MDVIP use Navigenics Test for Medicine? - March 18th, 2010 [March 18th, 2010]
- Why did P&G invest in Navigenics? - March 23rd, 2010 [March 23rd, 2010]
- PGx in DTCG? Doesn't stand up to Useful testing. - March 25th, 2010 [March 25th, 2010]
- End of Gene Patents? - March 29th, 2010 [March 29th, 2010]
- Sherpa Accepting Chief Medical Officership - April 3rd, 2010 [April 3rd, 2010]
- The Rumors of My Death........ - April 20th, 2010 [April 20th, 2010]
- Happy DNA Day! - April 25th, 2010 [April 25th, 2010]
- 99 USD, DNA day and patient letters - April 25th, 2010 [April 25th, 2010]
- 2C19, Navigenics and Clinical Reality. - May 1st, 2010 [May 1st, 2010]
- Coriell Personalized Medicine Collaborative rising - May 7th, 2010 [May 7th, 2010]
- Personal Genomes in Clinical Care. Quake paper is a waste! - May 11th, 2010 [May 11th, 2010]
- Personal Genomes in Clinical Care. Quake paper Falls Short! - May 13th, 2010 [May 13th, 2010]
- Last post edited by Drew - May 13th, 2010 [May 13th, 2010]
- GateKeeper? FCUK U! - May 13th, 2010 [May 13th, 2010]
- GateKeeper? F! U! - May 15th, 2010 [May 15th, 2010]
- Potential of genomic medicine, LOST - May 19th, 2010 [May 19th, 2010]
- How Bad Can a House Investigation be for DTC Genomics? - May 20th, 2010 [May 20th, 2010]